I wonder if the generics market has inculcated a kind of loose respect for patents in some companies. Particularly in India, where bypassing the rules to get the much needed drugs to a poorer market has led to a few loose interpretations of IP that may have spilled over to other dealings.
Different issue but I remember well ACL's woes in trying to get accurate sales data from Dr Reddy's with the royalty payments being miniscule and at the same time the investor outreach presentations from Dr R talking a totally different picture. They couldnt even keep their story consistent.
There are no end of lawsuits with these Mylan guys regarding their acquisitions and I am beginning to understand why. Be interesting to see if a possible arbitration call POH's way results in a lot of fluff and blustering from Mylan or some real action to pay up. They plainly dont like parting with a quid.
POH Price at posting:
2.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)